Company intelligence / Profile preview

Corbin Therapeutics

Montreal, Quebec, Canada

Ownership: Private
Development stage: Other

Overview

Corbin is in the hit-to-lead drug discovery stage, using proprietary in vitro and in vivo models to identify and optimize small molecule inhibitors of USP15, a novel target implicated in neuroinflammation and multiple sclerosis. No clinical data are available yet[1][3][8].

Therapeutic areas: ImmunologyNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Proteorex TherapeuticsUniversity of Dundee (Drug Discovery Unit)McGill University (licensing partnership)

Beyond the preview

Go deeper on Corbin Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Corbin Therapeutics.

Explore the full profile